肺癌的主要亚型非小细胞肺腺癌有比较大的概率可以靶向治疗，对于亚裔的非小细胞肺腺癌患者来说，EGFR基因突变概率非常高，可以达到50%的突变 ...

Immunohistochemistry is the primary option, as long as the cases classified as 2+ or equivocal are re-evaluated by in situ hybridization. Mechanisms of EGFR upregulation are dependent on the ...

with a widely used immunohistochemistry kit. The therapeutic dependence of EGFR modulation on the degree of receptor expression continues to be controversial; Pirker et al. 1 provide no details as ...

Datopotamab deruxtecan (Dato-DXd) has been granted Priority Review from the US FDA for advanced EGFR-mutated non-small cell lung cancer (NSCLC) following prior therapies.